Arbutus Biopharma
ABUS
ABUS
99 hedge funds and large institutions have $149M invested in Arbutus Biopharma in 2021 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 31 increasing their positions, 23 reducing their positions, and 14 closing their positions.
Holders
99
Holders Change
+8
Holders Change %
+8.79%
% of All Funds
1.74%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
23
Increased
31
Reduced
23
Closed
14
Calls
$13.5M
Puts
$7.71M
Net Calls
+$5.81M
Net Calls Change
+$8M
Top Buyers
| 1 |
1
Millennium Management
New York
|
$4.38M |
| 2 |
2
Nuveen Asset Management
Chicago,
Illinois
|
$4.87M |
| 3 |
3
Barclays
London,
United Kingdom
|
$2.73M |
| 4 |
4
SG Americas Securities
New York
|
$2.57M |
| 5 |
5
State Street
Boston,
Massachusetts
|
$7.11M |
Top Sellers
| 1 |
RI
1
RTW Investments
New York
|
$20.3M |
| 2 |
2
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
$198K |
| 3 |
CAC
3
Cowen and Company
New York
|
$1.07M |
| 4 |
4
Two Sigma Advisers
New York
|
$497K |
| 5 |
5
Point72 Asset Management
Stamford,
Connecticut
|
$3.84M |
